2,6-Diphenylpyridine-4-carbonyl chloride | 18780-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,6-Diphenylpyridine-4-carbonyl chloride
• CAS: 18780-00-2
• 化学式: C₁₈H₁₂ClNO
• 分子量: 293.752
• InChiKey: RYSVXJZLQSAPBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6-Diphenylpyridine-4-carbonyl chloride 、 N-Boc-哌嗪 在 三乙胺 作用下， 以 氯仿 为溶剂， 以38.8 g的产率得到tert-butyl 4-(2,6-diphenylisonicotinoyl)piperazine-1-carboxylate
  参考文献：
  名称：

  (4-Piperidinyl)-piperazine: A new platform for acetyl-CoA carboxylase inhibitors

  摘要：

  Acetyl-CoA carboxylases (ACCs), the rate limiting enzymes in de novo lipid synthesis, play important roles in modulating energy metabolism. The inhibition of ACC has demonstrated promising therapeutic potential for treating obesity and type 2 diabetes mellitus in transgenic mice and preclinical animal models. We describe herein the synthesis and structure-activity relationships of a series of disubstituted (4-piperidinyl)-piperazine derivatives as a new platform for ACC1/2 non-selective inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.012
• 作为产物：
  描述：

  2,6-联苯基异烟酸 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 3.0h， 生成 2,6-Diphenylpyridine-4-carbonyl chloride
  参考文献：
  名称：

  (4-Piperidinyl)-piperazine: A new platform for acetyl-CoA carboxylase inhibitors

  摘要：

  Acetyl-CoA carboxylases (ACCs), the rate limiting enzymes in de novo lipid synthesis, play important roles in modulating energy metabolism. The inhibition of ACC has demonstrated promising therapeutic potential for treating obesity and type 2 diabetes mellitus in transgenic mice and preclinical animal models. We describe herein the synthesis and structure-activity relationships of a series of disubstituted (4-piperidinyl)-piperazine derivatives as a new platform for ACC1/2 non-selective inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.012

文献信息

• [EN] MALIC ENZYME INHIBITORS<br/>[FR] INHIBITEURS D'ENZYME MALIQUE
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2021074898A1

  公开（公告）日：2021-04-22

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.

  本发明涉及一种新型化合物，可用作苹果酸酶（ME）抑制剂，以及用于制备这些化合物的方法和利用这些化合物治疗由ME介导的疾病，如人类的癌症（例如胰腺导管腺癌（PDAC））。
• Malic enzyme inhibitors
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD

  公开号：US11225480B2

  公开（公告）日：2022-01-18

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.

  本发明涉及可用作苹果酸酶（ME）抑制剂的新型化合物、其制备工艺以及这些化合物用于治疗由ME介导的疾病，如人类癌症（如胰腺导管腺癌（PDAC））。这些新型化合物具有符合式 I 的结构 或其药学上可接受的盐、立体异构体或氚代类似物，其中 X、R1、R2 和 Y 如本文所述。
• MALIC ENZYME INHIBITORS
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD

  公开号：US20210115038A1

  公开（公告）日：2021-04-22

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.